Aflibercept biosimilar (HEXAL/Sandoz)

N/A

Report date: 2024/11/19 14:54:13

Base Information

Drug NameAflibercept biosimilar (HEXAL/Sandoz)
Drug Alias NameAflibercept-abzvENZEEVUAfqlirSOK-583A1SOK583A1 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetes ComplicationsRetinal Vein OcclusionWet age-related macular degeneration +[6] 
Global Approved IndicationsDiabetes ComplicationsRetinal Vein OcclusionWet age-related macular degeneration +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/08/09
Country/TerritoryCzechiaBulgariaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSandozHexal
China Registration ClassN/A

Develop Information

Active CompaniesSandozSandoz IncSandoz Gmbh
Inactive CompaniesN/A
Active IndicationsDiabetes ComplicationsRetinal Vein OcclusionWet age-related macular degeneration +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A